New combo therapy for cervical cancer shows promise in early trial
NCT ID NCT00957411
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested whether adding the targeted drug cetuximab to standard chemoradiation (cisplatin plus radiation) improves outcomes for people with locally advanced cervical cancer (stages IB2 to IIIB). 76 participants were randomly assigned to receive either chemoradiation alone or chemoradiation plus cetuximab. The study measured recurrence-free survival at 2 years and treatment side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cetuximab (a targeted antibody) and cisplatin (chemotherapy)
What this could lead to
If successful, this could show that adding cetuximab to standard chemoradiation improves recurrence-free survival for locally advanced cervical cancer.
What could go wrong
This is a small, early-phase trial (76 people) and results may not apply broadly. Adding cetuximab could increase side effects without clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Curie Hopital
Paris, 75248, France